Current Report Filing (8-k)
January 10 2017 - 8:50AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 9, 2017
(Date of earliest event reported)
ABIOMED, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
Delaware
|
|
04-2743260
|
(State or other Jurisdiction of Incorporation)
|
|
(IRS Employer Identification Number)
|
001-09585
(Commission File Number)
22 Cherry Hill Drive
Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978) 646-1400
(Registrants Telephone Number, including Area Code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On January 9, 2017, we issued a press release
reporting preliminary unaudited revenue results for our third quarter ended December 31, 2016. A copy of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not
be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release dated January 9, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
Abiomed, Inc.
|
|
|
By:
|
|
/s/ Michael J. Tomsicek
|
|
|
Michael J. Tomsicek
Vice President and Chief
Financial Officer
(Principal Accounting and Financial Officer)
|
Date: January 10, 2017
Exhibit Index
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press release dated January 9, 2017.
|
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024